Nuravax is at the forefront of developing innovative immunotherapy solutions aimed at combating neurodegenerative diseases such as Alzheimer's and Parkinson's. Central to their approach is the proprietary MultiTEP platform, which is designed to create highly specific vaccine therapies that leverage the patient's immune system to target and eliminate pathological proteins from the bloodstream before they can cause neuronal damage. The MultiTEP platform utilizes a combination of diverse T-helper epitopes and a universal synthetic peptide, PADRE, to activate both naive and memory T-helper cells, ensuring a robust immune response. This method not only enhances antibody production but also aims to overcome common immunotherapy challenges, particularly in elderly patients who may experience immunosenescence.

The MultiTEP platform has shown promising preclinical results, generating strong immunogenic responses in various animal models, including mice, rabbits, and non-human primates. By attaching B-cell epitopes from disease-related proteins to the MultiTEP framework, Nuravax aims to produce high-titer recombinant protein vaccines that can effectively cross the blood-brain barrier. This strategy is designed to prevent the formation of harmful brain plaques and oligomers, thereby preserving normal brain function and potentially delaying the onset of neurodegenerative diseases. Through their commitment to advancing the science of neurological disorders, Nuravax is positioned to make significant contributions to the field of immunotherapy.

United States

Our mission is to develop effective and affordable preventive vaccines for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Using our universal vaccine platform for Alzheimer’s, our goal is to induce antibody titers high enough to penetrate the blood-brain barrier and prevent pathological plaques, fibrils, and oligomers to delay disease onset in cognitively unimpaired people at risk of Alzheimer’s.

Nuravax

Company Details